Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.09.21.753320

FFPE-CUTAC: A Single Assay, Multiple Layers

Abstract

Background: Archival biobanks of formalin-fixed paraffin-embedded (FFPE) specimens represent a vast and underused resource for retrospective molecular studies linked to clinical follow-up. However, fixation-induced chemical modification and nucleic acid fragmentation limit scalable genomic and transcriptomic profiling. FFPE-CUTAC (Cleavage Under Targeted Accessible Chromatin) is an RNA polymerase II-targeted DNA assay specifically designed to profile regulatory activity in FFPE tissue. Here, we assess its archival robustness, information content, compatibility with RNA-seq, and ability to recover copy-number alterations. Results: In meningioma and breast cancer cohorts, we benchmarked FFPE-CUTAC against matched fresh-frozen RNA-seq, FFPE RNA-seq and FFPE whole-genome sequencing. For FFPE specimens spanning up to 25 years, FFPE-CUTAC showed no systematic collection-year-associated decline in library yield or signal-quality metrics. In contrast, FFPE RNA-seq is more affected by the FFPE tissue degradation and specimen age on read composition, gene-body coverage, and gene detection. By measuring RNA polymerase II occupancy on chromatin rather than mature RNA abundance, FFPE-CUTAC is less constrained by transcript half-life, polyadenylation or transcript-capture design. FFPE-CUTAC extends beyond gene regions to non-coding regulatory elements, while the shared gene-level signals supported its integration with existing RNA-seq cohorts for large-scale, long-term clinical association study. FFPE-CUTAC libraries also retain DNA dosage information and can be used to recover chromosome-arm gain, loss and intact states with 96% concordance to matched whole-genome sequencing. Conclusions: By converting routinely preserved pathology sections into integrated regulatory and copy-number profiles, FFPE-CUTAC provides a practical foundation for constructing clinically annotated disease maps to support molecular stratification, prognostic modeling and treatment-association studies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Niu, Y., Xu, Q., Mak, C. Y., Xu, Y., Parmar, A., Zevin, A., Khyzha, N., Paranal, R., Holland, E., Ahmad, K., Henikoff, S., Zheng, Y.. 2026-09-22. FFPE-CUTAC: A Single Assay, Multiple Layers. https://doi.org/10.64898/2026.09.21.753320

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

An expanded, phenotypically distinct tumor cell subset with low HPV mRNA increases recurrence risk

Human papillomavirus-related (HPV+) cancers harbor a subset of tumor cells expressing certain senescence-related transcripts and reduced levels of HPV mRNAs. We aimed to define this HPV-low population's biologic traits and clinical significance via integrated analysis of recurrence-prone human HPV+ oropharyngeal cancers (OPCs) and patient-derived xenografts (PDXs) of variable therapy sensitivity. Single-cell mRNA sequencing of PDXs and human tumors detected gene expression profiles in HPV-low cells indicating lack of senescence or terminal differentiation and intact tumorigenic capacity. HPV-low cells in cisplatin-refractory PDXs and particular human OPCs differentially upregulated multiple pathways linked to aggressive tumor biology, including RAS signaling, IL-6 signaling, and EMT. Predicted loss of cell-cell interactions among HPV-low cells reflected reduced epithelial identity, further supporting their more aggressive biology. Accordingly, the size of the pre-treatment HPV-low fraction had strong, independent association with recurrence risk. Genetic subclones within OPCs varied widely in content of HPV-low cells, which were enriched in particular lineages. Our findings uncover novel pro-tumor functions of HPV-low cells and support a central role for them in therapy resistance as well as potential utility as a clinical biomarker. Further elucidating mechanisms of cooperativity and plasticity between HPV-low and high states holds promise to reveal targets in treatment-refractory HPV+ malignancies.

cancer biology↗

Discovery of molecular glues for modulating MHC presentation of cancer neoantigens

Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.

cancer biology↗

mRNA-LNP vaccination induces microenvironment remodeling and generation of tissue-resident memory T cells in glioblastoma

Glioblastoma remains highly refractory to immunotherapy, in part because of a profoundly immunosuppressive tumour microenvironment that limits effective T-cell responses. Although mRNA vaccines can induce anti-tumour immunity, how they reshape the glioblastoma immune ecosystem to support durable tumour control is not well understood. Here we use an immunocompetent EGFRvIII-driven syngeneic glioblastoma model and antigen-specific mRNA lipid nanoparticle (mRNA-LNP) vaccination to define the cellular and spatial mechanisms underlying therapeutic response. In our model, vaccination induced durable EGFRvIII-specific humoral and cellular immunity, resulting in complete tumour eradication and long-term protection against intracranial rechallenge. Integrative analyses incorporating flow cytometry, tumour interstitial fluid profiling, multiplex immunostaining, spatial transcriptomics and ligand-receptor modelling demonstrated extensive remodelling of the tumour microenvironment following vaccination. Early tumour control was associated with expansion of pro-inflammatory and antigen-presenting myeloid populations, increased cytotoxic CD8 T-cell infiltration and activation, enhanced interferon-responsive signalling, and the formation of immune-supportive spatial niches enriched for antigen presentation and chemokine-mediated cellular communication. Vaccination promoted inflammatory chemokine relay networks centred on the CXCL16-CXCR6 axis, a pathway linked to tissue residency programming in the central nervous system. Functional depletion studies identified CD4 and CD8 T cells as essential mediators of therapeutic efficacy, while durable protection was maintained by tumour-specific brain-resident memory CD8 T cells that persisted despite peripheral lymphocyte depletion. Together, these findings identify T-cell-driven microenvironmental remodelling as a critical mechanism linking mRNA vaccination to the establishment of long-term brain-resident anti-tumour immunity in glioblastoma.

cancer biology↗